Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
NCT ID: NCT03640884
Last Updated: 2021-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30000 participants
OBSERVATIONAL
2019-02-18
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
NCT05023382
Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.
NCT04641364
A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition
NCT05788588
Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis
NCT06436768
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
NCT05027308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Xueshuantong-Injection
Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
Xueshuantong-Injection
Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xueshuantong-Injection
Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhong Wang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhong Wang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhong Wang, M.D.
Role: STUDY_DIRECTOR
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Jinmin Liu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jizhou City Hospital
Hengshui, Hebei, China
Tongbai County People's Hospital
Nanyang, Henan, China
Lingbao 3th People's Hospital
Sanmenxia, Henan, China
People's Hospital of Dancheng County
Zhoukou, Henan, China
Dongxihu District People's Hospital
Wuhan, Hubei, China
Donghai Country People's Hospital
Lianyungang, Jiangsu, China
People's Hospital of Yichun City
Yichun, Jiangxi, China
Central Hospital of Wafangdian City
Dalian, Liaoning, China
Lingyuan City Central Hospital
Lingyuan, Liaoning, China
Chinse Medical Hospital of Yangxin County
Binzhou, Shandong, China
Weihai Wendeng District People's Hospital
Weihai, Shandong, China
Yangcheng County People's Hospital
Jincheng, Shanxi, China
Lingshi Country People's Hospital
Jinzhong, Shanxi, China
Shanxi Yuanping First People's Hospital
Yuanping, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhuci Li
Role: primary
Yuqian Liu
Role: primary
Wenhui Li
Role: primary
Yuwang Yang
Role: primary
Hanqiao Wang
Role: primary
Liangliang Xia
Role: primary
Huilin Leng
Role: primary
Shuying Bai
Role: primary
Bingyi Qin
Role: primary
Jinguo Zhao
Role: primary
Wangtai Cheng
Role: primary
Xiaoqin Wu
Role: primary
Yutian Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Xueshuantong--V2.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.